Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: A comparative study.

[1]  Bruno Sarmento,et al.  Lipid Architectonics for Superior Oral Bioavailability of Nelfinavir Mesylate: Comparative in vitro and in vivo Assessment , 2018, AAPS PharmSciTech.

[2]  N. K. Jain,et al.  Transferrin functionalized chitosan-PEG nanoparticles for targeted delivery of paclitaxel to cancer cells. , 2016, Colloids and surfaces. B, Biointerfaces.

[3]  N. K. Jain,et al.  Ligand anchored poly(propyleneimine) dendrimers for brain targeting: Comparative in vitro and in vivo assessment. , 2016, Journal of colloid and interface science.

[4]  Gil Navon,et al.  Glucosamine and N-acetyl glucosamine as new CEST MRI agents for molecular imaging of tumors , 2016, Scientific Reports.

[5]  V. Sali,et al.  Relative apoptotic potential and specific G1 arrest of stigmasterol and cinnamic acid isolated from the brown algae Padina gymnospora in HeLa and A549 cells , 2016 .

[6]  Sakhrat Khizroev,et al.  Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles , 2016, Scientific Reports.

[7]  P. Kazansky,et al.  Corrigendum: Revealing the nanoparticles aspect ratio in the glass-metal nanocomposites irradiated with femtosecond laser , 2016, Scientific reports.

[8]  N. K. Jain,et al.  Synthesis and characterization of dendro-PLGA nanoconjugate for protein stabilization. , 2015, Colloids and surfaces. B, Biointerfaces.

[9]  R. Lutz.  Targeting the folate receptor for the treatment of ovarian cancer , 2015 .

[10]  D. Serie,et al.  Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors , 2015, PloS one.

[11]  Tamer Refaat,et al.  Cancer active targeting by nanoparticles: a comprehensive review of literature , 2015, Journal of Cancer Research and Clinical Oncology.

[12]  A. Alavi,et al.  Oncogene pathway activation in mammary tumors dictates FDG-PET uptake. , 2014, Cancer research.

[13]  M. K. Naskar,et al.  Synthesis of mesoporous Stöber silica nanoparticles: the effect of secondary and tertiary alkanolamines , 2014, Journal of Sol-Gel Science and Technology.

[14]  Ying Shi,et al.  Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties. , 2013, Chemical communications.

[15]  N. K. Jain,et al.  Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates , 2012, Journal of drug targeting.

[16]  D. O'Shannessy,et al.  Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease , 2012, SpringerPlus.

[17]  T. Tsakiridis,et al.  Expression of the glucose transporters GLUT1, GLUT3, GLUT4 and GLUT12 in human cancer cells , 2012, BMC Proceedings.

[18]  Adelailson Peixoto,et al.  Computer-assisted coloring and illuminating based on a region-tree structure , 2012, SpringerPlus.

[19]  M. Bryś,et al.  Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers , 2012, Pathology & Oncology Research.

[20]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[21]  Jay Landers,et al.  Entering the Mainstream , 2010 .

[22]  M. Lotz,et al.  Differential metabolic effects of glucosamine and N-acetylglucosamine in human articular chondrocytes. , 2009, Osteoarthritis and cartilage.

[23]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[24]  N. K. Jain,et al.  Novel PEGylated PPI Dendritic Nanostructures for Sustained Delivery of Anti-Inflammatory Agent , 2008 .

[25]  T. Bein,et al.  Colloidal suspensions of functionalized mesoporous silica nanoparticles. , 2008, ACS nano.

[26]  A. Keating,et al.  Functional properties and genomics of glucose transporters. , 2007, Current genomics.

[27]  Khaled Greish,et al.  Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines , 2007, Journal of drug targeting.

[28]  Chi V Dang,et al.  Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.

[29]  L. Kelemen,et al.  The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander? , 2006, International journal of cancer.

[30]  M. Carrasco,et al.  Differential subcellular distribution of glucose transporters GLUT1–6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues , 2006, Journal of cellular physiology.

[31]  H. Shmeeda,et al.  Pros and Cons of the Liposome Platform in Cancer Drug Targeting , 2006, Journal of liposome research.

[32]  D. Norris,et al.  BMC Biotechnology BioMed Central Methodology article A simple technique for quantifying apoptosis in 96-well plates , 2005 .

[33]  J. Best,et al.  Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.

[34]  Peng Huang,et al.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.

[35]  H. Yamaguchi,et al.  Expression of glucose transporter 5 by microglia in human gliomas , 2004, Neuropathology and applied neurobiology.

[36]  M. Ratnam,et al.  Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. , 2004, Advanced drug delivery reviews.

[37]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[38]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[39]  J. Best,et al.  Differential expression of GLUT12 in breast cancer and normal breast tissue. , 2003, Cancer letters.

[40]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.